Are you a Health Professional? Jump over to the doctors only platform. Click Here

Xeloda – A New Standard of Care in Metastatic Breast Cancer

Print Friendly, PDF & Email

Breast cancer remains the most common cause of cancer mortality amongst females in western society. Metastatic disease develops in 30-40% of patients and treatment strategies continue to seek management regimens that will allow an increased quality and quantity of survival.

Xeloda (capcitabine), an oral fluoropyrimidinecarbamate, was designed to generate 5-Fluorouracil (5-FU) directly within the tumour cell, thus minimising the systemic exposure and subsequent gastrointestinal toxicities seen with intravenous 5-FU. The oral formulation allows for a convenient delivery of therapy, which can be given outside the hospital or clinic setting.

Click on the link above to read the attached report by Associate Professor Michael Green.

Print Friendly, PDF & Email


Posted On: 4 March, 2003
Modified On: 3 December, 2013


Created by: myVMC